Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-03-10
2011-11-08
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000
Reexamination Certificate
active
08053408
ABSTRACT:
The present invention provides methods for reducing body weight in a mammal using Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 4970154 (1990-11-01), Chang
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5106627 (1992-04-01), Aebischer et al.
patent: 5217889 (1993-06-01), Roninson et al.
patent: 5234784 (1993-08-01), Aslam et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5272071 (1993-12-01), Chappel
patent: 5364791 (1994-11-01), Vegeto et al.
patent: 5489743 (1996-02-01), Robinson et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5557032 (1996-09-01), Mak
patent: 5585089 (1996-12-01), Queen et al.
patent: 5589362 (1996-12-01), Bujard et al.
patent: 5593875 (1997-01-01), Wurm et al.
patent: 5635399 (1997-06-01), Kriegler et al.
patent: 5650298 (1997-07-01), Bujard et al.
patent: 5654168 (1997-08-01), Bujard et al.
patent: 5672510 (1997-09-01), Eglitis et al.
patent: 5676954 (1997-10-01), Brigham
patent: 5679559 (1997-10-01), Kim et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5811234 (1998-09-01), Roninson et al.
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 6150098 (2000-11-01), Zhang
patent: 6639063 (2003-10-01), Edwards
patent: 6716626 (2004-04-01), Itoh
patent: 7259248 (2007-08-01), Itoh
patent: 7408047 (2008-08-01), Thomason
patent: 7491697 (2009-02-01), Beals
patent: 2001/0012628 (2001-08-01), Agarwal et al.
patent: 2002/0081663 (2002-06-01), Conklin
patent: 2002/0164713 (2002-11-01), Itoh
patent: 2003/0220246 (2003-11-01), Conklin
patent: 2004/0018499 (2004-01-01), Lal
patent: 2004/0185494 (2004-09-01), Itoh
patent: 2004/0259780 (2004-12-01), Glasebrook
patent: 2005/0037457 (2005-02-01), Itoh
patent: 2005/0176631 (2005-08-01), Heuer
patent: 2007/0036806 (2007-02-01), Glaesner
patent: 2007/0128619 (2007-06-01), Itoh
patent: 2007/0142278 (2007-06-01), Beals
patent: 2007/0237768 (2007-10-01), Glaesner
patent: 2007/0238657 (2007-10-01), Itoh
patent: 2007/0265200 (2007-11-01), Glaesner
patent: 2007/0293430 (2007-12-01), Frye
patent: 2007/0299007 (2007-12-01), Frye
patent: 2008/0071065 (2008-03-01), Thomason
patent: 2008/0071066 (2008-03-01), Thomason
patent: 2008/0103096 (2008-05-01), Frye
patent: 2008/0255045 (2008-10-01), Cujec
patent: 2008/0261236 (2008-10-01), Kuro-o
patent: 2008/0261875 (2008-10-01), Etgen
patent: 2009/0074776 (2009-03-01), Itoh
patent: 0036676 (1981-09-01), None
patent: 0058481 (1982-08-01), None
patent: 0088046 (1983-09-01), None
patent: 0133988 (1985-03-01), None
patent: 0143949 (1985-06-01), None
patent: 0154316 (1985-09-01), None
patent: 0401384 (1990-12-01), None
patent: 0505500 (1992-09-01), None
patent: 0315456 (1994-06-01), None
patent: 0546073 (1997-09-01), None
patent: 90/04036 (1990-04-01), None
patent: 91/09955 (1991-07-01), None
patent: 91/10425 (1991-07-01), None
patent: 91/10470 (1991-07-01), None
patent: 91/10741 (1991-07-01), None
patent: 93/15722 (1993-08-01), None
patent: 94/02602 (1994-02-01), None
patent: 94/20069 (1994-09-01), None
patent: 94/28122 (1994-12-01), None
patent: 95/05452 (1995-02-01), None
patent: 95/34670 (1995-12-01), None
patent: 96/11953 (1996-04-01), None
patent: 96/32478 (1996-10-01), None
patent: 96/33735 (1996-10-01), None
patent: 96/37609 (1996-11-01), None
patent: 96/40958 (1996-12-01), None
patent: 96/41865 (1996-12-01), None
patent: 97/31899 (1997-09-01), None
patent: 97/34631 (1997-09-01), None
patent: 99/10494 (1999-03-01), None
patent: 00/24782 (2000-05-01), None
patent: 00/54813 (2000-09-01), None
patent: 01/18172 (2001-03-01), None
patent: 01/18209 (2001-03-01), None
patent: 01/32678 (2001-05-01), None
patent: 01/36640 (2001-05-01), None
patent: 01/38357 (2001-05-01), None
patent: 01/49849 (2001-07-01), None
patent: 01/72957 (2001-10-01), None
patent: 03/011213 (2003-02-01), None
patent: 03/059270 (2003-07-01), None
patent: 2004110472 (2004-12-01), None
patent: 2005061712 (2005-07-01), None
patent: 2005072769 (2005-08-01), None
patent: 2005/091944 (2005-10-01), None
patent: 2005/113606 (2005-12-01), None
patent: 2006/028595 (2006-03-01), None
patent: 2006/028714 (2006-03-01), None
patent: 2006/050247 (2006-05-01), None
patent: 2006/065582 (2006-06-01), None
patent: 2006/078463 (2006-07-01), None
patent: 2007/055789 (2007-05-01), None
patent: 2007/100695 (2007-09-01), None
patent: 2008/011633 (2008-01-01), None
patent: 2008/121563 (2008-10-01), None
patent: 2008/151258 (2008-12-01), None
patent: 2008/153705 (2008-12-01), None
patent: 2009/020802 (2009-02-01), None
Nishimura et al. (2000), “Identification of a novel FGF, FGF-21, preferentially expressed in the liver(I).” Biochim Biophys Acta 21: 203-6.
Parthiban et al., 2006, “MSH2 is essential for the preservation of genome integrity and prevents homeologous recombination in the mossPhyscomitrella patens” Nucleic Acids Res. 34: 232-42.
Plotnikov et al. (1999), “Structural Basis for FGF Receptor Dimerization and Activation” Cell 98: 641-650.
Riechmann et al., 1998, “Reshaping human antibodies for therapy” Nature 332: 323-27.
Sidman et al., 1983, “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid” Biopolymers 22: 547-56.
Trouiller, et al. (2006), “MSH2 is essential for the preservation of genome integrity and prevents homeologous recombination in the mossPhyscomitrella patens” Nucleic Acids Research vol. 34, (1): 232-242.
Verhoeyen et al., 1988, “Reshaping human antibodies: grafting an antilysozyme activity” Science 239: 1534-36.
Wente et al. (2006), “Fibroblast Growth Factor-21 Improves Pancreatic B-Cell Function and Survival by Activation of Extracellular Signal-Regulated Kinase ½and Akt Signaling Pathways” Diabetes 55: 2470-2478.
Wischke & Schwendeman, 2008, “Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles” Int. J. Pharm. 364: 298-327.
Xu et al., (2009) “Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice” Diabetes 58(1):250-9.
Yie et al., 2009, “FGF21 N- and C-termini play different roles in receptor interaction and activation” FEBS Lett. 583:19-24.
The ADHR consortium (2000), “Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.” Nature Genetics 26: 345-348.
Arner et al. (2008) “FGF21 attenuates lipolysis in human adipocytes—A possible link to improved insulin sensitivity” FEBS Letters 582: 1725-1730.
Artuc et al. (1999), “Mast cells and their mediators in cutaneous wound healing—active participants or innocent bystanders?” Exp. Dermatol. 8: 1-16.
Bayer et al., 1990, “Protein biotinylation” Meth. Enz. 184: 138-63.
Beck and Podolsky (1999), “Growth factors in inflammatory bowel disease.” Inflamm. Bowel Dis. 5: 44-60.
Bishop (1996), “Chromosomal insertion of foreign DNA,” Reprod. Nutr. Dev. 36(6): 607-18.
Bork et al. (1996), “Go hunting in sequence databases but watch out for the traps,” Trends Genet. 12(10): 425-27.
Bork et al. (1998), “Predicting functions from protein sequences—where are the bottlenecks?” Nature Genetics 18(4): 313-18.
Bork (2000), “Powers and pitfalls in sequence analysis: the 70% hurdle,” Genome Res. 10(4): 398-400.
Branch (1998), “A good antisense molecule is hard to find.” Trends Biochem Sci. 23(2): 45-50.
Brenn
Liu Benxian
Thomason Arlen
Amgen Inc.
McDonnell & Boehnen Hulbert & Berghoff
Saoud Christine J
LandOfFree
Methods for treating obesity using fibroblast growth... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating obesity using fibroblast growth..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating obesity using fibroblast growth... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4259787